Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability of Brepocitinib in Healthy Men
NCT03770039Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brepocitinib in plaque psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and 2 more, sponsored by Pfizer. Primary endpoints: Mass balance recovered in urine and Mass balance recovered in feces. Started Dec 2018; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)systemic lupus erythematosus (SLE)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03770039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770039.